IMF Patient & Family Webinar - Back to Basics: From Testing to Tailored Therapy

IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie will moderate presentations with the following myeloma experts:
Paul Richardson, MD (Dana-Farber Cancer Institute, Boston, MA)
Saad Usmani, MD (Memorial Sloan Kettering Cancer Center, New York, NY)
Mary Steinbach, DNP, APRN (Hunstman Cancer Institute, Salt Lake City, UT)
0:05:42 - Recommended Testing and Monitoring: 2022 Algorithms - Brian Durie, MD.
A discussion which will cover required testing for diagnosis and monitoring, new testing approaches, as well as Mass Spectrometry and molecular analyses. 2022/2023 Myeloma care guidelines throughout the disease course will also be presented, with an open discussion of key options.
0:46:40 - Frontline Options - Paul Richardson, MD
Frontline therapy will be discussed in the context of the role of autologous stem cell transplant (ASCT) and the use of quadruplets (four-drug combinations) vs triplets (three-drug combinations). The results of the DETERMINATION Trial (Triplet VRd +/- upfront ASCT) will be the starting point for discussions and questions.
1:36:02 - Managing Myeloma Care -Mary Steinbach, DNP, APRN
Questions about the overall approach to supportive care will be answered. It is particularly important to review and open discussions about special side effects and/or toxicities brought about by new and emerging therapies.
2:03:16 - Relapse Options: FDA Approved/Clinical Trials - Saad Usmani, MD
How to manage relapsing disease from the perspective of both currently approved and available therapies, as well as clinical trial options. He will particularly focus on the potential role of bispecific antibodies in new and emerging treatment paradigms-an area with many questions that need to be addressed.
Download Slides here: www.myeloma.org/videos/imf-pa...
_______________
Improving Lives | Finding the Cure
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Subscribe to our channel: / imfmyeloma
Visit our website at: www.myeloma.org
Find us online:
Facebook: @myeloma | / myeloma
Twitter: @IMFMyeloma | / imfmyeloma
Instagram: @imfmyeloma | / imfmyeloma
LinkedIn: / international-myeloma-...
Support the IMF! bit.ly/WskQHC
Category
Nonprofits & Activism
License
Standard UA-cam License
In most cases, captions are autogenerated by UA-cam.

[@veera6394]

Very good information to have for someone who is on the verge being labeled as a myeloma patient. So many drugs are available is good news, but is it so simple to switch from one medicine to the other considering what kind of pain and side effects the patient has to bear?
I value this site so much.
Thank you.